Biliary tract carcinomas: From chemotherapy to targeted therapy

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 2, 2013, Pages 136-148

  Marino, Donatella ^a   Leone, Francesco ^a   Cavalloni, Giuliana ^a   Cagnazzo, Celeste ^a   Aglietta, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biliary tract carcinoma; Chemotherapy; Cholangiocarcinoma; Gallbladder carcinoma; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN; NITRIC OXIDE; OXALIPLATIN; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SORAFENIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANEMIA; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; DRUG MEGADOSE; DRUG RESPONSE; EPIGENETICS; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA; EPIGENOMICS; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING;

EID: 84872610350     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.06.006     Document Type: Review

References (151)

1. Khan S.A., Toledano M.B., Taylor-Robinson S.D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008, 10:77-82.
2. Charbel H., Al-Kawas F.H. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Current Gastroenterology Reports 2011, 13:182-187.
3. Boberg K.M., Schrumpf E., Bergquist A., et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Journal of Hepatology 2000, 32:374-380.
4. Shin H.R., Oh J.K., Masuyer E., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Science 2010, 101:579-585.
5. Alpini G.P.R., LaRusso N.F. The pathobiology of biliary epithelia. The liver: biology and pathobiology 2001, 421-435. Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. I.M. Arias (Ed.).
6. Jaiswal M., LaRusso N.F., Burgart L.J., Gores G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Research 2000, 60:184-190.
7. Jaiswal M., LaRusso N.F., Gores G.J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. American Journal of Physiology - Gastrointestinal and Liver Physiology 2001, 281:G626-G634.
8. Schottenfeld D., Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA: A Cancer Journal for Clinicians 2006, 56:69-83.
9. Wise C., Pilanthananond M., Perry B.F., et al. Mechanisms of biliary carcinogenesis and growth. World Journal of Gastroenterology 2008, 14:2986-2989.
10. Prawan A., Buranrat B., Kukongviriyapan U., et al. Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. Journal of Cancer Research and Clinical Oncology 2009, 135:515-522.
11. Pinlaor S., Sripa B., Ma N., et al. Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World Journal of Gastroenterology 2005, 11:4644-4649.
12. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
13. Tsujii M., Kawano S., Tsuji S., et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
14. Yoon J.H., Higuchi H., Werneburg N.W., et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002, 122:985-993.
15. Werneburg N.W., Yoon J.H., Higuchi H., Gores G.J. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. American Journal of Physiology - Gastrointestinal and Liver Physiology 2003, 285:G31-G36.
16. Zhang L., Jiang L., Sun Q., et al. Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Molecular and Cellular Biochemistry 2007, 305:19-26.
17. Laird A.D., Li G., Moss K.G., et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Molecular Cancer Therapeutics 2003, 2:461-469.
18. Quesnelle K.M., Boehm A.L., Grandis J.R. STAT-mediated EGFR signaling in cancer. Journal of Cellular Biochemistry 2007, 102:311-319.
19. De Luca A., Carotenuto A., Rachiglio A., et al. The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology 2008, 214:559-567.
20. Leone F., Cavalloni G., Pignochino Y., et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clinical Cancer Research 2006, 12:1680-1685.
21. Gwak G.Y., Yoon J.H., Shin C.M., et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. Journal of Cancer Research and Clinical Oncology 2005, 131:649-652.
22. Nakazawa K., Dobashi Y., Suzuki S., et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. Journal of Pathology 2005, 206:356-365.
23. Terada T., Ashida K., Endo K., et al. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998, 33:325-331.
24. Endo K., Yoon B.I., Pairojkul C., et al. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002, 36:439-450.
25. Pignochino Y., Sarotto I., Peraldo-Neia C., et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010, 10:631.
26. Zheng J., Zhu Y.M. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. Hepatobiliary & Pancreatic Diseases International 2007, 6:412-415.
27. Settakorn J., Kaewpila N., Burns G.F., Leong A.S. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. Journal of Clinical Pathology 2005, 58:1249-1254.
28. Sirica A.E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 2008, 14:7033-7058.
29. Kim H.J., Yoo T.W., Park D.I., et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry, its prognostic implication in node-positive patients. Annals of Oncology 2007, 18:892-897.
30. Gruenberger B., Schueller J., Heubrandtner U., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer, a phase 2 study. The Lancet Oncology 2010, 11:1142-1148.
31. Bekaii-Saab T., Phelps M.A., Li X., et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. Journal of Clinical Oncology 2011, 29:2357-2363.
32. Tsuda H., Satarug S., Bhudhisawasdi V., et al. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Molecular Carcinogenesis 1992, 6:266-269.
33. Kang Y.K., Kim W.H., Lee H.W., et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Laboratory Investigation 1999, 79:477-483.
34. Suto T., Habano W., Sugai T., et al. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. Journal of Surgical Oncology 2000, 73:158-163.
35. Isa T., Tomita S., Nakachi A., et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology 2002, 49:604-608.
36. Xu R.F., Sun J.P., Zhang S.R., et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomedicine and Pharmacotherapy 2011, 65:22-26.
37. Tannapfel A., Sommerer F., Benicke M., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
38. Saetta A.A., Papanastasiou P., Michalopoulos N.V., et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Archiv 2004, 445:179-182.
39. Riener M.O., Bawohl M., Clavien P.A., Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes, Chromosomes and Cancer 2008, 47:363-367.
40. Isomoto H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio-carcinoma due to SOCS3 epigenetic silencing. Digestion 2009, 79(Suppl. 1):2-8.
41. Isomoto H., Kobayashi S., Werneburg N.W., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42:1329-1338.
42. Kobayashi S., Werneburg N.W., Bronk S.F., et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005, 128:2054-2065.
43. Park J., Tadlock L., Gores G.J., Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999, 30:1128-1133.
44. Tadlock L., Patel T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001, 33:43-51.
45. Braconi C., Huang N., Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 51:881-890.
46. Meng F., Wehbe-Janek H., Henson R., et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008, 27:378-386.
47. Selaru F.M., Olaru A.V., Kan T., et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009, 49:1595-1601.
48. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
49. Meng F., Henson R., Lang M., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
50. Jarnagin W.R., Fong Y., DeMatteo R.P., et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of Surgery 2001, 234:507-517. [discussion 517-509].
51. Zhu A.X., Hong T.S., Hezel A.F., Kooby D.A. Current management of gallbladder carcinoma. Oncologist 2010, 15:168-181.
52. Endo I., Shimada H., Tanabe M., et al. Prognostic significance of the number of positive lymph nodes in gallbladder cancer. Journal of Gastrointestinal Surgery 2006, 10:999-1007.
53. Brunner T.B., Eccles C.L. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlentherapie und Onkologie 2010, 186:672-680.
54. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology 1996, 7:593-600.
55. Takada T., Kato H., Matsushiro T., et al. Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU)+adriamycin+mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Gan to Kagaku Ryoho 1996, 23:707-714.
56. Sharma A., Dwary A.D., Mohanti B.K., et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology 2010, 28:4581-4586.
57. Choi C.W., Choi I.K., Seo J.H., et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. American Journal of Clinical Oncology 2000, 23:425-428.
58. Falkson G., MacIntyre J.M., Moertel C.G. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984, 54:965-969.
59. Ducreux M., Van Cutsem E., Van Laethem J.L., et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. European Journal of Cancer 2005, 41:398-403.
60. Raderer M., Hejna M.H., Valencak J.B., et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999, 56:177-180.
61. Penz M., Kornek G.V., Raderer M., et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Annals of Oncology 2001, 12:183-186.
62. Kubicka S., Rudolph K.L., Tietze M.K., et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology 2001, 48:783-789.
63. Gallardo J.O., Rubio B., Fodor M., et al. A phase II study of gemcitabine in gallbladder carcinoma. Annals of Oncology 2001, 12:1403-1406.
64. Lin M.H., Chen J.S., Chen H.H., Su W.C. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003, 49:154-158.
65. Tsavaris N., Kosmas C., Gouveris P., et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Investigational New Drugs 2004, 22:193-198.
66. Eng C., Ramanathan R.K., Wong M.K., et al. A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. American Journal of Clinical Oncology 2004, 27:565-569.
67. Park J.S., Oh S.Y., Kim S.H., et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japanese Journal of Clinical Oncology 2005, 35:68-73.
68. von Delius S., Lersch C., Schulte-Frohlinde E., et al. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005, 5:61.
69. Gelibter A., Malaguti P., Di Cosimo S., et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005, 104:1237-1245.
70. Okusaka T., Ishii H., Funakoshi A., et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology 2006, 57:647-653.
71. Milella M., Gelibter A.J., Pino M.S., et al. Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer. Oncologist 2010, 15:e1-e4.
72. Feisthammel J., Schoppmeyer K., Mossner J., et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. American Journal of Clinical Oncology 2007, 30:319-324.
73. Harvey J.H., Smith F.P., Schein P.S. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. Journal of Clinical Oncology 1984, 2:1245-1248.
74. Lee S., Oh S.Y., Kim B.G., et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. American Journal of Clinical Oncology 2009, 32:348-352.
75. Patt Y.Z., Hassan M.M., Lozano R.D., et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clinical Cancer Research 2001, 7:3375-3380.
76. Takada T., Kato H., Matsushiro T., et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994, 51:396-400.
77. Eckel F., Lersch C., Assmann G., Schulte-Frohlinde E. Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. Annals of Oncology 2000, 11:762-763.
78. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine 2011, 364:1817-1825.
79. Cereda S., Passoni P., Reni M., et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer 2010, 116:2208-2214.
80. Yamashita Y., Taketomi A., Itoh S., et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Japanese Journal of Clinical Oncology 2010, 40:24-28.
81. Wagner A.D., Buechner-Steudel P., Moehler M., et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. British Journal of Cancer 2009, 101:1846-1852.
82. Yamashita Y., Taketomi A., Fukuzawa K., et al. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Research 2006, 26:771-775.
83. Morine Y., Shimada M., Ikegami T., et al. Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepato-Gastroenterology 2009, 56:307-312.
84. Taieb J., Mitry E., Boige V., et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Annals of Oncology 2002, 13:1192-1196.
85. Nehls O., Klump B., Arkenau H.T., et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. British Journal of Cancer 2002, 87:702-704.
86. Kim T.W., Chang H.M., Kang H.J., et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Annals of Oncology 2003, 14:1115-1120.
87. Hong Y.S., Lee J., Lee S.C., et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology 2007, 60:321-328.
88. Sanz-Altamira P.M., Ferrante K., Jenkins R.L., et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998, 82:2321-2325.
89. Ducreux M., Rougier P., Fandi A., et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Annals of Oncology 1998, 9:653-656.
90. Kobayashi K., Tsuji A., Morita S., et al. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 2006, 6:121.
91. Kim Y.J., Im S.A., Kim H.G., et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Annals of Oncology 2008, 19:99-103.
92. Nehls O., Oettle H., Hartmann J.T., et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. British Journal of Cancer 2008, 98:309-315.
93. Lim J.Y., Jeung H.C., Mun H.S., et al. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anti-Cancer Drugs 2008, 19:631-635.
94. Chatni S.S., Sainani R.S., Mehta S.A., Mohandas K.M. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer. Journal of Cancer Research and Therapeutics 2008, 4:151-155.
95. Chen J.S., Chao Y., Yang T.S., et al. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. Cancer Chemotherapy and Pharmacology 2009, 65:151-157.
96. Riechelmann R.P., Townsley C.A., Chin S.N., et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007, 110:1307-1312.
97. Iyer R.V., Gibbs J., Kuvshinoff B., et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Annals of Surgical Oncology 2007, 14:3202-3209.
98. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. Journal of Clinical Oncology 2005, 23:2332-2338.
99. Boxberger F., Jungert B., Brueckl V., et al. Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas. Anti-Cancer Drugs 2003, 14:87-90.
100. Murad A.M., Guimaraes R.C., Aragao B.C., et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. American Journal of Clinical Oncology 2003, 26:151-154.
101. Hsu C., Shen Y.C., Yang C.H., et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. British Journal of Cancer 2004, 90:1715-1719.
102. Alberts S.R., Al-Khatib H., Mahoney M.R., et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma, a North Central Cancer Treatment Group phase II trial. Cancer 2005, 103:111-118.
103. Sasaki T., Isayama H., Nakai Y., et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology 2010, 65:1101-1107.
104. Kanai M., Yoshimura K., Tsumura T., et al. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology 2011, 67:1429-1434.
105. Thongprasert S., Napapan S., Charoentum C., Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Annals of Oncology 2005, 16:279-281.
106. Charoentum C., Thongprasert S., Chewaskulyong B., Munprakan S. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World Journal of Gastroenterology 2007, 13:2852-2854.
107. Malik I.A., Aziz Z., Zaidi S.H., Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. American Journal of Clinical Oncology 2003, 26:174-177.
108. Doval D.C., Sekhon J.S., Gupta S.K., et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. British Journal of Cancer 2004, 90:1516-1520.
109. Andre T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals of Oncology 2004, 15:1339-1343.
110. Kim S.T., Park J.O., Lee J., et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006, 106:1339-1346.
111. Julka P.K., Puri T., Rath G.K. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary & Pancreatic Diseases International 2006, 5:110-114.
112. Lee G.W., Kang J.H., Kim H.G., et al. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. American Journal of Clinical Oncology 2006, 29:127-131.
113. Park B.K., Kim Y.J., Park J.Y., et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Journal of Gastroenterology and Hepatology 2006, 21:999-1003.
114. Giuliani F., Gebbia V., Maiello E., et al. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology 2006, 17(Suppl. 7):vii73-vii77.
115. Verderame F., Russo A., Di Leo R., et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Annals of Oncology 2006, 17(Suppl. 7):vii68-vii72.
116. Harder J., Riecken B., Kummer O., et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. British Journal of Cancer 2006, 95:848-852.
117. Lee J., Kim T.Y., Lee M.A., et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology 2008, 61:47-52.
118. Manzione L., Romano R., Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007, 73:311-315.
119. Meyerhardt J.A., Zhu A.X., Stuart K., et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Digestive Diseases and Sciences 2008, 53:564-570.
120. Kim H.J., Lee N.S., Lee S.C., et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemotherapy and Pharmacology 2009, 64:371-377.
121. Andre T., Reyes-Vidal J.M., Fartoux L., et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. British Journal of Cancer 2008, 99:862-867.
122. Sharma A., Mohanti B., Raina V., et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemotherapy and Pharmacology 2010, 65:497-502.
123. Jang J.S., Lim H.Y., Hwang I.G., et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemotherapy and Pharmacology 2010, 65:641-647.
124. Li J., Merl M., Lee M.X., et al. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opinion on Drug Safety 2010, 9:207-213.
125. Goldstein D., Gainford M.C., Brown C., et al. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology 2011, 67:519-525.
126. Williams K.J., Picus J., Trinkhaus K., et al. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) 2010, 12:418-426.
127. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer 2007, 96:896-902.
128. Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. British Journal of Cancer 2009, 101:621-627.
129. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine 2010, 362:1273-1281.
130. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007, 25:1960-1966.
131. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. Journal of Clinical Oncology 2006, 24:3069-3074.
132. Lim H.Y.L.J., Chang H., Kim J.S., et al. Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. Journal of Clinical Oncology 2011, 29(Suppl.). [abstr LBA4032].
133. Ramanathan R.K., Belani C.P., Singh D.A., et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology 2009, 64:777-783.
134. Chang P.Y., Cheng M.F., Lee H.S., et al. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie 2010, 33:45-47.
135. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. The Lancet Oncology 2010, 11:38-47.
136. Malka D.F.L., Mendiboure J., de la Fouchardiere C., Viret F., Assenat E. A multi-center, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. Journal of Clinical Oncology 2009, 27(Suppl.):15s. [abstr 4520].
137. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. The Lancet Oncology 2010, 11:48-54.
138. Lubner S.J., Mahoney M.R., Kolesar J.L., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. Journal of Clinical Oncology 2010, 28:3491-3497.
139. Blechacz B.R., Smoot R.L., Bronk S.F., et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009, 50:1861-1870.
140. LaRocca R.V., Hicks M.D., Mull L., Foreman B. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. Journal of Gastrointestinal Cancer 2007, 38:154-156.
141. Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British Journal of Cancer 2010, 102:68-72.
142. Moehler M.H.S.C.C., Kanzler S., Woerns M.A., et al. A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer. Journal of Clinical Oncology 2011, 29(Suppl.). [abstr 4077].
143. Alberts S.R., Fitch T.R., Kim G.P., et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. American Journal of Clinical Oncology 2011, 10.1097/COC.0b013e3182118cdf.
144. Shanafelt T., Zent C., Byrd J., et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leukemia and Lymphoma 2010, 51:2222-2229.
145. Ramalingam S.S., Belani C.P., Mack P.C., et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Journal of Thoracic Oncology 2010, 5:1279-1284.
146. Cabebe E.C., Fisher G.A., Sikic B.I. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Investigational New Drugs 2012, 30(3):1082-1087.
147. Iwamoto H., Torimura T., Nakamura T., et al. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 2011, 13:187-197.
148. de Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011, 29:1067-1074.
149. Rizell M., Andersson M., Cahlin C., et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. International Journal of Clinical Oncology 2008, 13:66-70.
150. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003, 98:1689-1700.
151. Furuse J., Okusaka T., Bridgewater J., et al. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Critical Reviews in Oncology/Hematology 2011, 80:31-39.